Table 4.
Clinical characteristics and outcomes in intervention group and control group patients after 6 months
| Intervention group | Control group | T-value | Sig. | |
|---|---|---|---|---|
| Mean (S.D.) | Mean (S.D.) | |||
| General overuse | 11.93 (2.15) | 12.63 (2.61) | 2.197 | 0.029a |
| General harm | 10.08 (2.25) | 10.67 (2.90) | 1.687 | 0.093 |
| Beneficial effect of pharmaceuticals | 15.35 (2.04) | 15.25 (2.15) | 0.356 | 0.722 |
| Beliefs about medicines | 35.36 (3.62) | 38.12 (4.43) | 5.055 | <0.0001a |
| Sensitive | 15.10 (2.56) | 15.39 (3.10) | 0.769 | 0.442 |
| Necessity beliefs | 19.00 (3.83) | 18.50 (4.19) | 0.939 | 0.349 |
| Concern beliefs | 12.05 (3.08) | 13.14 (3.97) | 2.278 | 0.024 |
| Treatment Satisfaction Questionnaire for Medication (TSQM) | 88.71 (10.77) | 82.89 (13.40) | 3.551 | <0.0001a |
| Estimated weights for EQ-5D | 0.68 (0.40) | 0.66 (0.38) | 0.356 | 0.722 |
| Montgomery–Åsberg Depression Scale | 20.65 (11.97) | 20.86 (12.54) | 0.129 | 0.897 |
| Medication Adherence Scale | 5.99 (1.88) | 4.94 (1.94) | 4.059 | <0.0001a |
aSignificantly different